17 research outputs found

    Improved Stability of Proline-Derived Direct Thrombin Inhibitors through Hydroxyl to Heterocycle Replacement

    No full text
    Modification of the previously disclosed (<i>S</i>)-<i>N</i>-(2-(aminomethyl)-5-chlorobenzyl)-1-((<i>R</i>)-2-hydroxy-3,3-dimethylbutanoyl)­pyrrolidine-2-carboxamide <b>2</b> by optimization of the P3 group afforded novel, low molecular weight thrombin inhibitors. Heterocycle replacement of the hydroxyl functional group helped maintain thrombin<i> in vitro</i> potency while improving the chemical stability and pharmacokinetic profile. These modifications led to the identification of compound <b>10</b>, which showed excellent selectivity over related serine proteases as well as <i>in vivo</i> efficacy in the rat arteriovenous shunt. Compound <b>10</b> exhibited significantly improved chemical stability and pharmacokinetic properties over <b>2</b> and may be utilized as a structurally differentiated preclinical tool comparator to dabigatran etexilate (<b>Pro-1</b>) to interrogate the on- and off-target effects of oral direct thrombin inhibitors
    corecore